Featured Publications

INOVIO is focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases. In the last several years INOVIO has had its data published in several prominent peer-reviewed medical journals including:

Filter by Category

HPV-Targeted

Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses
Science Translational Medicine — October 2012
Disease TargetCervical Dysplasia ProductVGX-3100
Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100
Molecular Therapy Oncolytics — January 2016
Disease TargetCervical Dysplasia ProductVGX-3100
Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy
Clinical Cancer Research — January 2018
Disease TargetCervical Dysplasia ProductVGX-3100
Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis
BMJ — July 2016
Disease TargetCervical Dysplasia ProductVGX-3100
Immune Therapy Targeting E6/E7 Oncogenes of Human Papillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis
Vaccines — January 2020
Disease TargetRRP ProductINO-3107
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer
Clinical Cancer Research — January 2019
Disease TargetHead & Neck Cancer ProductMEDI0457
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
The Lancet — September 2015
Disease TargetCervical Dysplasia ProductVGX-3100

Immuno-Oncology (Non HPV-Associated)

Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT
Molecular Therapy — November 2017
Disease TargethTERT ProductINO-5401
Highly Optimized DNA Vaccine Targeting Human Telomerase Reverse Transcriptase Stimulates Potent Antitumor Immunity
Cancer Immunology Research — September 2013
Disease TargethTERT ProductINO-5401
A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity
Molecular Therapy — February 2017
Disease TargetWT1 ProductINO-5401
CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens
Molecular Therapy — March 2020
Disease TargetPSA ProductINO-5151
Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses
Human Vaccines — January 2011
Disease TargetPSA, PSMA ProductINO-5401

Infectious Diseases (Non HPV-Associated)

Synthetic Consensus HIV-1 DNA Induces Potent Cellular Immune Responses and Synthesis of Granzyme B, Perforin in HIV Infected Individuals
Molecular Therapy — March 2015
Disease TargetHIV ProductPENNVAX-GP
HIV-1 Env DNA Vaccine plus Protein Boost Delivered by EP Expands B- and T-Cell Responses and Neutralizing Phenotype In Vivo
PLoS ONE — December 2013
Disease TargetHIV ProductPENNVAX-GP
Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine
Vaccine — September 2011
Disease TargetHIV ProductPENNVAX-GP
Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers
The Journal of Infectious Diseases — March 2019
Disease TargetEbola ProductINO-4201
Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA Vaccines
The Journal of Infectious Diseases — October 2018
Disease TargetEbola ProductINO-4201
Rapid response to an emerging infectious disease – Lessons learned from development of a synthetic DNA vaccine targeting Zika virus
Microbes and Infection — December 2018
Disease TargetZika ProductINO-4600
Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization
The Journal of Infectious Diseases — July 2018
Disease TargetZika ProductINO-4600
DNA vaccination protects mice against Zika virus-induced damage to the testes
Nature Communications — June 2017
Disease TargetZika ProductINO-4600
In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine
npj Vaccines — November 2016
Disease TargetZika ProductINO-4600
A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates
Science Translational Medicine — August 2015
Disease TargetMERS ProductINO-4700
Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine
Vaccine — May 2018
Disease TargetInfluenza
An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model
Nature Communications — September 2017
Disease TargetPseudomonas
Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus
The Journal of Infectious Diseases — March 2016
Disease TargetChikungunya
Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy
Scientific Reports — July 2015
Disease TargetDengue
IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T-cell frequency and increases virus-specific T-cell responses
Journal of Hepatology — February 2020
Disease TargetHepatitis C ProductGLS-6150
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial
The Lancet Infectious Diseases — July 2019
Disease TargetMERS ProductINO-4700
Safety and Immunogenicity of an Anti–Zika Virus DNA Vaccine — Preliminary Report
The New England Journal of Medicine — October 2017
Disease TargetZika ProductINO-4600

dMAb™ (DNA-Encoded Monocolonal Antibodies)

Other Development Candidates

DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity
JCI Insight — April 2019
Disease TargetHER2

Delivery Technology/Proprietary Smart Device

Electroporation delivery of DNA vaccines: prospects for success
Current Opinion in Immunology — June 2011
Disease TargetDelivery ProductCELLECTRA®
A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle
Vaccine — September 2011
Disease TargetDelivery ProductCELLECTRA
Integration of needle-free jet injection with advanced electroporation delivery enhances the magnitude, kinetics, and persistence of engineered DNA vaccine induced immune responses
Vaccine — June 2019
Disease TargetDelivery ProductCELLECTRA

COVID-19

Immunogenicity of a DNA vaccine candidate for COVID-19
Nature Communications — May 2020
Disease TargetCOVID-19 ProductINO-4800
571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster
Open Forum Infectious Diseases — December 2021
Disease TargetCOVID-19 ProductINO-4800
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial
The Journal of Infectious Diseases — January 2022
Disease TargetCOVID-19 ProductINO-4800
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants
npj Vaccines — October 2021
Disease TargetCOVID-19 ProductINO-4800